Company registration number 06467439 (England and Wales)
POOLE BAY PHARMACY LTD
UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 SEPTEMBER 2025
PAGES FOR FILING WITH REGISTRAR
POOLE BAY PHARMACY LTD
CONTENTS
Page
Balance sheet
1 - 2
Notes to the financial statements
3 - 7
POOLE BAY PHARMACY LTD
BALANCE SHEET
AS AT
30 SEPTEMBER 2025
30 September 2025
- 1 -
2025
2024
Notes
£
£
£
£
Fixed assets
Tangible assets
4
30,374
34,293
Current assets
Stocks
69,344
85,413
Debtors
5
249,496
237,882
Cash at bank and in hand
61,149
106,864
379,989
430,159
Creditors: amounts falling due within one year
6
(314,579)
(348,477)
Net current assets
65,410
81,682
Total assets less current liabilities
95,784
115,975
Creditors: amounts falling due after more than one year
7
(15,000)
(37,500)
Provisions for liabilities
(7,594)
(8,573)
Net assets
73,190
69,902
Capital and reserves
Called up share capital
8
200
200
Profit and loss reserves
72,990
69,702
Total equity
73,190
69,902
POOLE BAY PHARMACY LTD
BALANCE SHEET (CONTINUED)
AS AT
30 SEPTEMBER 2025
30 September 2025
- 2 -

For the financial year ended 30 September 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

T he members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The directors of the company have elected not to include a copy of the profit and loss account within the financial statements.true

The financial statements were approved by the board of directors and authorised for issue on 25 February 2026 and are signed on its behalf by:
Dr L D A Brad
Dr G A Edwards
Director
Director
Dr S Morgan
Dr R Schuster Bruce
Director
Director
Company registration number 06467439 (England and Wales)
POOLE BAY PHARMACY LTD
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 SEPTEMBER 2025
- 3 -
1
Accounting policies
Company information

Poole Bay Pharmacy Ltd is a private company limited by shares incorporated in England and Wales. The registered office is Westbourne Medical Centre, Milburn Road, Westbourne, Dorset, UK, BH4 9HJ.

1.1
Basis of preparation

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary a mounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

1.2
Going concern

A true t the time of approving the financial statements, t he directors have a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future. Thus t he directors continue to adopt the going concern basis of accounting in preparing the financial statements.

1.3
Revenue

Turnover is recognised as the right to consideration obtained through the performance of contractual obligations, net of VAT.

The nature, timing of satisfaction of performance obligations and significant payment terms of the company's major sources of revenue are as follows:

Revenue from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have passed to the buyer (usually on dispatch of the goods), the amount of revenue can be measured reliably, it is probable that the economic benefits associated with the transaction will flow to the entity and the costs incurred or to be incurred in respect of the transaction can be measured reliably.

Revenue from contracts for the provision of professional services is recognised by reference to the stage of completion when the stage of completion, costs incurred and costs to complete can be estimated reliably. The stage of completion is calculated by comparing costs incurred, mainly in relation to contractual hourly staff rates and materials, as a proportion of total costs. Where the outcome cannot be estimated reliably, revenue is recognised only to the extent of the expenses recognised that are recover able.

1.4
Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Fixtures and fittings
10% on reducing balance
Computers
25% on reducing balance
Motor vehicles
25% on reducing balance

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

POOLE BAY PHARMACY LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 SEPTEMBER 2025
1
Accounting policies
(Continued)
- 4 -
1.5
Impairment of fixed assets

At each reporting period end date, the company reviews the carrying amounts of its tangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any). Where it is not possible to estimate the recoverable amount of an individual asset, the company estimates the recoverable amount of the cash-generating unit to which the asset belongs.

Recoverable amount is the higher of fair value less costs to sell and value in use. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset for which the estimates of future cash flows have not been adjusted.

If the recoverable amount of an asset (or cash-generating unit) is estimated to be less than its carrying amount, the carrying amount of the asset (or cash-generating unit) is reduced to its recoverable amount. An impairment loss is recognised immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the impairment loss is treated as a revaluation decrease.

Recognised impairment losses are reversed if, and only if, the reasons for the impairment loss have ceased to apply. Where an impairment loss subsequently reverses, the carrying amount of the asset (or cash-generating unit) is increased to the revised estimate of its recoverable amount, but so that the increased carrying amount does not exceed the carrying amount that would have been determined had no impairment loss been recognised for the asset (or cash-generating unit) in prior years. A reversal of an impairment loss is recognised immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the reversal of the impairment loss is treated as a revaluation increase.

1.6
Stocks

Stocks are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items.

At each reporting date, an assessment is made for impairment. Any excess of the carrying amount of stocks over its estimated selling price less costs to complete and sell is recognised as an impairment loss in profit or loss. Reversals of impairment losses are also recognised in profit or loss.

1.7
Cash and cash equivalents

Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

1.8
Financial instruments

Debtors and creditors with no stated interest rate and receivable or payable within one year are recorded at transaction price. Any losses arising from impairment are recognised in the profit and loss account.

Loans and borrowings are initially recognised at the transaction price including transaction costs. Subsequently, they are measured as amortised cost using the effective interest rate methos, less impairment.

Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

POOLE BAY PHARMACY LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 SEPTEMBER 2025
1
Accounting policies
(Continued)
- 5 -
Classification of financial liabilities

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.

Basic financial liabilities

Basic financial liabilities, including creditors, bank loans, loans from fellow group companies and preference shares that are classified as debt, are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future paymen ts discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. A m ounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

1.9
Taxation

The tax expense represents the sum of the tax currently payable and deferred tax.

Current tax

The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the profit and loss account because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The company’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.

Deferred tax

Deferred tax liabilities are generally recognised for all timing differences and deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Such assets and liabilities are not recognised if the timing difference arises from goodwill or from the initial recognition of other assets and liabilities in a transaction that affects neither the tax profit nor the accounting profit.

The carrying amount of deferred tax assets is reviewed at each reporting end date and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered. Deferred tax is calculated at the tax rates that are expected to apply in the period when the liability is settled or the asset is realised. Deferred tax is charged or credited in the profit and loss account, except when it relates to items charged or credited directly to equity, in which case the deferred tax is also dealt with in equity. Deferred tax assets and liabilities are offset when the company has a legally enforceable right to offset current tax assets and liabilities and the deferred tax assets and liabilities relate to taxes levied by the same tax authority.

1.10
Employee benefits

The costs of short-term employee benefits are recognised as a liability and an expense, unless those costs are required to be recognised as part of the cost of stock or fixed assets.

The cost of any unused holiday entitlement is recognised in the period in which the employee’s services are received.

Termination benefits are recognised immediately as an expense when the company is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

POOLE BAY PHARMACY LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 SEPTEMBER 2025
1
Accounting policies
(Continued)
- 6 -
1.11
Retirement benefits

The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charges to profit or loss in the period to which they relate.

1.12
Leases
As lessee

Rentals payable under operating leases are charged to profit and loss on a straight line basis over the period of the lease.

2
Judgements and key sources of estimation uncertainty

In the application of the company’s accounting policies, the directors are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

3
Employees

The average monthly number of persons (including directors) employed by the company during the year was:

2025
2024
Number
Number
Total
23
20
4
Tangible fixed assets
Fixtures and fittings
Computers
Motor vehicles
Total
£
£
£
£
Cost
At 1 October 2024
83,770
25,911
12,083
121,764
Additions
-
0
2,097
-
0
2,097
At 30 September 2025
83,770
28,008
12,083
123,861
Depreciation and impairment
At 1 October 2024
64,692
18,814
3,965
87,471
Depreciation charged in the year
1,908
2,078
2,030
6,016
At 30 September 2025
66,600
20,892
5,995
93,487
Carrying amount
At 30 September 2025
17,170
7,116
6,088
30,374
At 30 September 2024
19,078
7,097
8,118
34,293
POOLE BAY PHARMACY LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 SEPTEMBER 2025
- 7 -
5
Debtors
2025
2024
Amounts falling due within one year:
£
£
Trade debtors
211,599
199,832
Other debtors
37,897
38,050
249,496
237,882
6
Creditors: amounts falling due within one year
2025
2024
£
£
Bank loans
22,500
22,500
Trade creditors
254,550
290,159
Taxation and social security
28,060
28,651
Other creditors
9,469
7,167
314,579
348,477
7
Creditors: amounts falling due after more than one year
2025
2024
£
£
Bank loans and overdrafts
15,000
37,500

The bank borrowings are secured by way of a fixed and floating charge against the company's assets

8
Called up share capital
2025
2024
2025
2024
Ordinary share capital
Number
Number
£
£
Issued and fully paid
Ordinary A of £1 each
100
100
100
100
Ordinary B of £1 each
100
100
100
100
200
200
200
200
9
Financial commitments, guarantees and contingent liabilities

Total commitments under operating leases amounted to £331,870 as at 30 September 2025 (2024: £271,118).

2025-09-30 2024-10-01 false false false 25 February 2026 CCH Software CCH Accounts Production 2025.300 No description of principal activity Dr L D A Brad Dr G A Edwards Dr S Morgan Dr R Schuster Bruce Dr G A Edwards 06467439 2024-10-01 2025-09-30 06467439 2025-09-30 06467439 2024-09-30 06467439 core:FurnitureFittings 2025-09-30 06467439 core:ComputerEquipment 2025-09-30 06467439 core:MotorVehicles 2025-09-30 06467439 core:FurnitureFittings 2024-09-30 06467439 core:ComputerEquipment 2024-09-30 06467439 core:MotorVehicles 2024-09-30 06467439 core:CurrentFinancialInstruments core:WithinOneYear 2025-09-30 06467439 core:CurrentFinancialInstruments core:WithinOneYear 2024-09-30 06467439 core:CurrentFinancialInstruments 2025-09-30 06467439 core:CurrentFinancialInstruments 2024-09-30 06467439 core:Non-currentFinancialInstruments 2025-09-30 06467439 core:Non-currentFinancialInstruments 2024-09-30 06467439 core:ShareCapital 2025-09-30 06467439 core:ShareCapital 2024-09-30 06467439 core:RetainedEarningsAccumulatedLosses 2025-09-30 06467439 core:RetainedEarningsAccumulatedLosses 2024-09-30 06467439 core:ShareCapitalOrdinaryShareClass1 2025-09-30 06467439 core:ShareCapitalOrdinaryShareClass1 2024-09-30 06467439 core:ShareCapitalOrdinaryShareClass2 2025-09-30 06467439 core:ShareCapitalOrdinaryShareClass2 2024-09-30 06467439 core:ShareCapitalOrdinaryShares 2025-09-30 06467439 core:ShareCapitalOrdinaryShares 2024-09-30 06467439 bus:Director1 2024-10-01 2025-09-30 06467439 bus:CompanySecretaryDirector1 2024-10-01 2025-09-30 06467439 bus:Director2 2024-10-01 2025-09-30 06467439 bus:Director3 2024-10-01 2025-09-30 06467439 core:FurnitureFittings 2024-10-01 2025-09-30 06467439 core:ComputerEquipment 2024-10-01 2025-09-30 06467439 core:MotorVehicles 2024-10-01 2025-09-30 06467439 2023-10-01 2024-09-30 06467439 core:FurnitureFittings 2024-09-30 06467439 core:ComputerEquipment 2024-09-30 06467439 core:MotorVehicles 2024-09-30 06467439 2024-09-30 06467439 bus:OrdinaryShareClass1 2024-10-01 2025-09-30 06467439 bus:OrdinaryShareClass2 2024-10-01 2025-09-30 06467439 bus:OrdinaryShareClass1 2025-09-30 06467439 bus:OrdinaryShareClass1 2024-09-30 06467439 bus:OrdinaryShareClass2 2025-09-30 06467439 bus:OrdinaryShareClass2 2024-09-30 06467439 bus:AllOrdinaryShares 2025-09-30 06467439 bus:AllOrdinaryShares 2024-09-30 06467439 bus:PrivateLimitedCompanyLtd 2024-10-01 2025-09-30 06467439 bus:SmallCompaniesRegimeForAccounts 2024-10-01 2025-09-30 06467439 bus:FRS102 2024-10-01 2025-09-30 06467439 bus:AuditExemptWithAccountantsReport 2024-10-01 2025-09-30 06467439 bus:Director4 2024-10-01 2025-09-30 06467439 bus:CompanySecretary1 2024-10-01 2025-09-30 06467439 bus:FullAccounts 2024-10-01 2025-09-30 xbrli:pure xbrli:shares iso4217:GBP